肥胖脓毒性休克患者对辅助性血管加压素的血流动力学反应减弱:生理性或剂量依赖性效应?
该研究为多中心登记数据的事后分析,纳入200例成人脓毒性休克患者,按体重指数分为正常体重(BMI<25 kg/m2)、超重(BMI 25-29.9 kg/m2)和肥胖(BMI≥30 kg/m2)三组,每15分钟记录去甲肾上腺素和血管加压素剂量。多变量线性混合效应模型评估启动血管加压素后2小时和5小时内去甲肾上腺素轨迹的组间差异及BMI与时间的交互作用,并二次分析纳入血管加压素剂量。结果显示正常体重患者模型估计去甲肾上腺素剂量每小时降低6.1%(95%CI 1.7-10.6),超重患者保持稳定(-2.0%,95%CI -6.3-2.4),肥胖患者每小时增加5.5%(95%CI 1.0-10.0);血管加压素剂量、时间与BMI的三重交互作用显著(p<0.001),较高血管加压素剂量与正常体重患者去甲肾上腺素需求降低相关,但在超重和肥胖患者中无此关联;按BMI调整的血管加压素剂量与固定剂量相比未显著改变去甲肾上腺素需求(所有p>0.70)。作者认为肥胖相关血管加压素抵抗可能由内在生理因素驱动而非剂量不足。
要点
- 肥胖脓毒性休克患者启动血管加压素后,模型估计去甲肾上腺素剂量每小时增加5.5%(95%CI 1.0-10.0),而正常体重患者每小时降低6.1%(95%CI 1.7-10.6)。
- 超重患者去甲肾上腺素剂量保持稳定(-2.0%,95%CI -6.3-2.4),与正常体重和肥胖患者均不同。
- 血管加压素剂量、时间与BMI的三重交互作用显著(p<0.001),较高血管加压素剂量仅与正常体重患者去甲肾上腺素需求降低相关,超重和肥胖患者无此关联。
- 按BMI调整的血管加压素剂量与固定剂量相比未显著改变去甲肾上腺素需求(所有p>0.70),提示肥胖相关抵抗非剂量不足所致。
- 作者认为肥胖相关血管加压素抵抗可能由内在生理因素驱动而非剂量不足。
适用人群与场景
- 多中心登记数据中的200例成人脓毒性休克患者,按BMI分组:正常体重(BMI<25 kg/m2)占33%,超重(BMI 25-29.9 kg/m2)占34.5%,肥胖(BMI≥30 kg/m2)占32.5%。
研究设计与关键结果
- 研究类型为多中心登记数据的事后分析,纳入200例成人脓毒性休克患者,按BMI分为正常体重(BMI<25 kg/m2)、超重(BMI 25-29.9 kg/m2)和肥胖(BMI≥30 kg/m2)三组,每15分钟记录去甲肾上腺素和血管加压素剂量。
- 多变量线性混合效应模型显示,启动血管加压素后模型估计去甲肾上腺素剂量在正常体重患者每小时降低6.1%(95%CI 1.7-10.6),超重患者保持稳定(-2.0%,95%CI -6.3-2.4),肥胖患者每小时增加5.5%(95%CI 1.0-10.0)。
- 血管加压素剂量、时间与BMI的三重交互作用显著(p<0.001),较高血管加压素剂量与正常体重患者去甲肾上腺素需求降低相关,但在超重和肥胖患者中无此关联。
- 按BMI调整的血管加压素剂量与固定剂量相比未显著改变去甲肾上腺素需求(所有p>0.70)。
证据类型、等级与局限
- 证据类型为多中心登记数据的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为肥胖相关血管加压素抵抗可能由内在生理因素驱动而非剂量不足,在肥胖脓毒性休克患者中启动血管加压素后需注意去甲肾上腺素需求可能不降反升。
- 按BMI调整血管加压素剂量与固定剂量相比未显著改变去甲肾上腺素需求(所有p>0.70),提示仅靠增加血管加压素剂量可能无法克服肥胖患者的抵抗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Obesity is increasingly prevalent in ICU patients, often requiring adjusted dosing due to altered drug pharmacodynamics. Arginine vasopressin (AVP) is used adjunctively to norepinephrine (NE) in septic shock, but its hemodynamic efficacy may vary with body mass index (BMI), potentially influencing NE-sparing effects.
METHODS: A post-hoc analysis of 200 adults with septic shock from a multicenter registry. Patients were grouped into normal weight (BMI<25 kg/m2), overweight (BMI 25-29.9 kg/m2) and obesity (BMI≥30 kg/m2). NE and AVP doses were recorded every 15 minutes. Multivariable linear mixed-effect models assessed between-group differences in NE trajectories within two and five hours after AVP initiation and the interaction between BMI and time, followed by a secondary analysis including AVP dosing.
RESULTS: Thirty-three percent were normal weight, 34.5% overweight and 32.5% obese. The model-estimated NE dose decreased by 6.1% (95%CI 1.7-10.6) per hour in normal weight patients, remained stable in overweight patients (-2.0%, 95%CI -6.3-2.4), and increased by 5.5% (95%CI 1.0-10.0) per hour in obese patients. The three-way interaction of AVP dose, time and BMI was significant (p<0.001), with higher AVP dose being associated with a decrease in NE requirements in normal weight patients but not in overweight and obese patients. BMI-adjusted AVP dosing did not significantly alter NE requirements compared to fixed dose (all p>0.70).
CONCLUSIONS: In septic shock patients, obesity is associated with increased NE requirement after AVP initiation, in contrast to the reduction observed in normal weight patients. Obesity-related resistance to AVP may be driven by intrinsic physiological factors rather than insufficient dosing.
参考来源
- Melchers M, Pickkers P, van Zanten ARH, et al. Attenuated hemodynamic response to adjunct vasopressin in obese septic shock patients: a physiological or dose-dependent effect? Crit Care. 2026. PMID: 41699685. doi:10.1186/s13054-026-05871-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。